Nipocalimab
(Anti-human FcRn mAb, human IgG1-Lambda2; M281; JNJ-80202135)
Catalog No.: PC-Ab1089Not For Human Use, Lab Use Only.
Nipocalimab (M281, JNJ-80202135) is a fully human IgG1 mAb that selectively bind, saturate, and block the IgG binding site on the endogenous neonatal fragment crystallizable receptor (FcRn). Nipocalimab has potential in treatment of SLE through lowering of pathogenic IgGs and immune complexes. The neonatal Fc receptor (also FcRn, IgG receptor FcRn large subunit p51, or Brambell receptor) is a protein that in humans is encoded by the FCGRT gene. It is an Fc receptor which is similar in structure
Nipocalimab (M281, JNJ-80202135) is a fully human IgG1 mAb that selectively bind, saturate, and block the IgG binding site on the endogenous neonatal fragment crystallizable receptor (FcRn). Nipocalimab has potential in treatment of SLE through lowering of pathogenic IgGs and immune complexes. The neonatal Fc receptor (also FcRn, IgG receptor FcRn large subunit p51, or Brambell receptor) is a protein that in humans is encoded by the FCGRT gene. It is an Fc receptor which is similar in structure to the MHC class I moleculethat functions to protect IgG and albumin from catabolism, mediates transport of IgG across epithelial cells, and is involved in antigen presentation by professional antigen presenting cells.
Physicochemical Properties
M.Wt
Formula
Human IgG1-Lambda2
Appearance
Solid
CAS No.
Storage
Solide Powder
-20 °C 12 Months; 4°C 6 Months
In Solvent
-80 °C 6 Months; -20°C 6 Months
Shipping
Solubility
PBS, pH 7.0
Contains no stabilizers or preservatives
